# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-336918
Filing Date
2026-08-06
Accepted
2026-08-06 08:45:41
Documents
74
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | ck0001991792-20260630.htm iXBRL | 10-Q | 1958299
2 | EX-10.2 | ck0001991792-ex10_2.htm | EX-10.2 | 84108
3 | EX-31.1 | ck0001991792-ex31_1.htm | EX-31.1 | 17271
4 | EX-31.2 | ck0001991792-ex31_2.htm | EX-31.2 | 17065
5 | EX-32.1 | ck0001991792-ex32_1.htm | EX-32.1 | 11062
6 | EX-32.2 | ck0001991792-ex32_2.htm | EX-32.2 | 11146
| Complete submission text file | 0001193125-26-336918.txt |  | 8941303

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | ck0001991792-20260630.xsd | EX-101.SCH | 1367374
78 | EXTRACTED XBRL INSTANCE DOCUMENT | ck0001991792-20260630_htm.xml | XML | 1513858

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1640 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1640 DALLAS TX 75247 (949) 409-3700
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

EIN.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41925 | Film No.: 261246400
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)